- Home
- TKNO vs PVLA Comparison
TKNO vs PVLA Comparison
Compare TKNO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- PVLA
- Stock Information
- Founded
- TKNO 1996
- PVLA 2015
- Country
- TKNO United States
- PVLA United States
- Employees
- TKNO N/A
- PVLA N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- PVLA Health Care
- Exchange
- TKNO Nasdaq
- PVLA Nasdaq
- Market Cap
- TKNO 256.9M
- PVLA 285.2M
- IPO Year
- TKNO 2021
- PVLA N/A
- Fundamental
- Price
- TKNO $4.35
- PVLA $54.15
- Analyst Decision
- TKNO
- PVLA Strong Buy
- Analyst Count
- TKNO 0
- PVLA 11
- Target Price
- TKNO N/A
- PVLA $56.64
- AVG Volume (30 Days)
- TKNO 221.4K
- PVLA 133.4K
- Earning Date
- TKNO 08-07-2025
- PVLA 08-14-2025
- Dividend Yield
- TKNO N/A
- PVLA N/A
- EPS Growth
- TKNO N/A
- PVLA N/A
- EPS
- TKNO N/A
- PVLA N/A
- Revenue
- TKNO $38,923,000.00
- PVLA N/A
- Revenue This Year
- TKNO $9.52
- PVLA N/A
- Revenue Next Year
- TKNO $15.20
- PVLA N/A
- P/E Ratio
- TKNO N/A
- PVLA N/A
- Revenue Growth
- TKNO 11.40
- PVLA N/A
- 52 Week Low
- TKNO $4.00
- PVLA $11.17
- 52 Week High
- TKNO $10.37
- PVLA $57.19
- Technical
- Relative Strength Index (RSI)
- TKNO 43.35
- PVLA 67.56
- Support Level
- TKNO $4.22
- PVLA $49.13
- Resistance Level
- TKNO $4.94
- PVLA $57.19
- Average True Range (ATR)
- TKNO 0.29
- PVLA 4.30
- MACD
- TKNO -0.00
- PVLA 0.15
- Stochastic Oscillator
- TKNO 16.75
- PVLA 81.32
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.